Global Acute Heart Failure Pipeline Review, H2 2016: Focus on 8 Companies & 9 Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2016" report to their offering.

Acute Heart Failure Acute heart failure is defined as sudden change in heart functions (inability of heart to pump enough blood to meet body's demand). Symptoms include shortness of breath, weakness, fatigue, irregular or fast heartbeat and coughing and wheezing. Predisposing factors include high blood pressure, diabetes, coronary artery disease, inherited heart defects, and a damaged or inflamed heart. Treatment includes angiotensin-converting enzyme (ACE) inhibitors, beta blockers, diuretics and surgery.

Acute Heart Failure pipeline therapeutics constitutes close to 9 molecules. which approximately 9 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2 and 2 respectively.

Acute Heart Failure - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Acute Heart Failure Overview
  3. Therapeutics Development
  4. Pipeline Products for Acute Heart Failure - Overview
  5. Pipeline Products for Acute Heart Failure - Comparative Analysis
  6. Acute Heart Failure - Therapeutics under Development by Companies
  7. Acute Heart Failure - Therapeutics under Investigation by Universities/Institutes
  8. Acute Heart Failure Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Acute Heart Failure - Products under Development by Companies
  13. Acute Heart Failure - Products under Investigation by Universities/Institutes
  14. Acute Heart Failure - Companies Involved in Therapeutics Development
  • Amgen Inc.
  • Capricor Therapeutics, Inc.
  • Eli Lilly and Company
  • Lee's Pharmaceutical Holdings Limited
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • PhaseBio Pharmaceuticals, Inc.
  • Trevena, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/wjzg3g/acute_heart

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs